Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITATE: felzartamab versus placebo in adults with Graves' disease
2026-526482-19-00Phase 2Authorised
- Sponsor
- Biogen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Graves' disease comparing Felzartamab with Placebo (2 arms). Primary endpoint: Percentage of participants who are euthyroid and off anti-thyroid drugs at Week 24. Planned start Oct 2026; status: authorised.
02
Drugs
felzartamab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2026-526482-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526482-19-00.